NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $16.64 +0.42 (+2.59%) As of 04/17/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsRatingsBuy This Stock About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BBC alerts:Sign Up Key Stats Today's Range$16.28▼$16.7250-Day Range$14.14▼$22.3352-Week Range$13.42▼$31.65Volume100,518 shsAverage Volume13,845 shsMarket Capitalization$7.49 millionAssets Under Management$10.03 millionDividend Yield1.44%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.Read More… Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.57%0.56%0.52%0.53%Other Expenses0.00%0.30%0.49%0.56%0.52%Total Expense0.79%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.66%-0.55%Net Expense0.79%0.61%0.63%0.58%0.60% Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address BBC ETF News HeadlinesFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | benzinga.comTech ETFs on the Rise After Four Weeks in Deep RedAugust 19, 2024 | theglobeandmail.comTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that could benefit.April 20, 2025 | Brownstone Research (Ad)Virtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatJuly 20, 2024 | lse.co.ukDrama at Trump trial as judge reprimands witness and clears courtMay 22, 2024 | bbc.comSee More Headlines BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $23.94 on January 1st, 2025. Since then, BBC stock has decreased by 30.5% and is now trading at $16.64. View the best growth stocks for 2025 here. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and General Electric (GE). Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings126 Fund Statistics Assets Under Management$10.03 million Average Daily Volume$115,579.00 Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume33 Put Options27 Call Options6 Short Interest13,500 shs Miscellaneous Outstanding Shares450,004Beta1.07 Creation Unit50,000 Creation Fee$500.00 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 BBC HoldingsXeris Biopharma (NASDAQ:XERS)Holding Weight: 1.88%Soleno Therapeutics (NASDAQ:SLNO)Holding Weight: 1.80%Akero Therapeutics (NASDAQ:AKRO)Holding Weight: 1.62%Liquidia (NASDAQ:LQDA)Holding Weight: 1.56%Mineralys Therapeutics (NASDAQ:MLYS)Holding Weight: 1.52%Arcutis Biotherapeutics (NASDAQ:ARQT)Holding Weight: 1.49%AnaptysBio (NASDAQ:ANAB)Holding Weight: 1.44%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 1.40%Summit Therapeutics (NASDAQ:SMMT)Holding Weight: 1.26%Belite Bio (NASDAQ:BLTE)Holding Weight: 1.22%Full Holdings DetailsBBC Sector ExposureBBC Industry Exposure This page (NYSEARCA:BBC) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
